A peer-reviewed article in The Lancet (July 2025) detailed the results of GALAXI-2 and GALAXI-3, which compared Tremfya to Stelara in Crohn’s disease. Tremfya achieved significantly greater clinical remission and endoscopic response rates at Week 48. In biologic-experienced patients, Tremfya outperformed Stelara in maintaining steroid-free remission and mucosal healing. Safety was comparable across arms, with mild infections as the most common adverse events. These head-to-head results establish guselkumab as not only an effective alternative but a superior IL-23p19 agent versus IL-12/23 inhibition in CD. The trial used consistent outcome definitions and blinded endoscopy readings, adding robustness to findings. As payer and clinician emphasis grows on comparative efficacy, this evidence may shift prescriber preference.

Citation: https://medicalxpress.com/news/2025-07-guselkumab-superior-efficacy-clinical-trials.html

Implication: These data may lead to increased Tremfya adoption in CD, especially in biologic-experienced patients.